Effects of tamoxifen on the human female genital tract: review of the literature

Tamoxifen is a non-steroidal triphenylethylene derivate, with clear antioestrogenic effects on the breast, that is orally administrated for the treatment of breast cancer and its prevention in a high-risk population. This article analyzes the effects of tamoxifen on the adult human female genital tract and considers its carcinogenicity in the gynaecological reproductive organs. It has been found that tamoxifen causes oestrogenic changes of the vaginal and cervical squammous epithelium and increases the incidence of cervical and endometrial polyps. The action of tamoxifen on the human endometrium in postmenopausal women is connected with simple oestrogenic effects including hyperplasia, while in others with endometrial cystic atrophy. In cases where tamoxifen induces endometrial polyps and hyperplasia, the extensive fibrosis accounts for difficulties in obtaining endometrial biopsy or resecting the polyps. In premenopausal patients tamoxifen disrupts the menstrual cycles and causes ovarian cysts, while in postmenopausal patients it induces ovarian cystic tumors and endometriomas. Also, postmenopausal patients treated with tamoxifen may develop endometriosis, adenomyosis and leiomyomata. In addition, randomized trials have shown a link between tamoxifen use in breast cancer patients and the development of endometrial carcinomas. Moreover, of note is the fact that the association of tamoxifen therapy with uterine mesenchymal neoplasms is higher than expected. In conclusion, the most worrying gynaecological side-effect of tamoxifen is the well-known increased risk of endometrial carcinomas. Women with breast cancer treated with tamoxifen should undergo annual gynaecological examination, but endometrial sampling should be obtained only in the event of endometrial bleeding.

Tamoxifen; Uterine carcinoma; Uterine polyp; Endometrial hyperplasia; Uterine sarcoma; Ovarian cyst

[1] Touraine Ph., Driguez P., Cartier I., Yaneva H., Kuttenn F., Mauvais-Jarvis L: "Lack of induction of endometrial hyperplasia with tamoxifen". Lancet, 1995, 345, 254.

[2] Jordan G.V.: "Long term adjuvant tamoxifen therapy for breast cancer". Breast Cancer Res. Treat., 1990, 15, 125.

[3] Buchanan R.B., Blarney R. W., Durrent K.R. et al.: "A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer". J. Clin. Oneal., 1986, 4, 1326.

[4] Cole M.P., Jones C.T.A., Todd I.D.H.: "A new antiestrogenic agent in late breast cancer: An early aproisal of ICI146,474". Br. J. Cancer. 1971, 25, 270.

[5] American College of Obstetrician and Gynecologists: “Tamoxifen and endometrial cancer". ACOG Committee Opinion No 169 Washington, DC, American College of Obstetricians and Gynaecologists, 1996.

[6] Nolvadex Adjuvant Organization: "Controlled trial of tamoxifen as a single agent in the management of early breast cancer". Br. J Cancer, 1988, 57, 608.

[7] Fisher B., Constantino J.P., Redmond C.K., Fisher E.R., Widkerham D.L.. Cronin W.M., and other NSABP contributors: "Endometrial cancer in tamoxifen-treated breast cancer patients findings for the National Surgical Adjuvant Breast and Bowel Projects (NSABP) B-14". J. Natl. Cancer Inst., 1994, 86, 527.

[8] Love R.R.: "Tamoxifen prophylaxis in breast cancer". Oncology (Huntingt), 1992, 6, 33.

[9] Barakat R., Wong G., Curtin J.P., Vlamis Y., Hoskins W.J.: "Tamoxifen use in breast cancer patients who subsequent develop corpus cancer is not associated with a higher incidence of adverse histologic features". Gynecol. Oncol., 1994, 55, 164.

[10] Malfetano J.H.: "Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients". Gynecol. Oneal., 1990, 39, 82.

[11] Anderson E., Howell A.: "The molecular biology of endocrine responsiveness in breast cancer". In: "Molecular Biology for Oncologists". Yarnold J.R., Stratton M., McM计Ian T.J. (eds.), London. Chapman & Hall, 1996, 217.

[12] Varras M., Spandidos D.A.: "Molecular biology of gynaecological cancer". In: "Gynaecological Oncology" (in Greek). Pektasidis D., Demopoulos M.-A. (eds.). Athens: Medical Publications Paschalidis P., 2001, 68.

[13] Jordan V.C.: "Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen". J. Natl. Cancer I., 1990, 82, 1662.

[14」Varras M.N., Zachos G., Spandidos D.A.: "Endometrial carcinoma in a breast cancer patient treated with tamoxifen: Activation of Kras proto-oncogene". Oncol. Rep., 1997, 4, 1045.

[15] Mourits J.E.. De Vries G.E., Willemse P.H.B., Ten Hoor K.A., Hollema H., Van der Zee A.G.J.: "Tamoxifen treatment and gyneco logic side effects: A review". Obst et. Gynecol., 2001, 97, 855.

[16] Ferrazzi E., Cartei G., Mattarazzo R., Fiorentino M.: "Estrogenlike action of tamoxifen on vaginal epithelium". B,: Med. J., 1977, 1, 1351.

[17] Boccardo F., Bruzzi P., Rubagotti A., Nicolo G., Rosso R.: "Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients". Oncology, 1981, 30, 281.

[18] Mortimer J.E., Boucher L., Baty J., Knapp D.L., Ryan E., Rowland J.: "Effect of tamoxifen on sexual t'Unctioning in patients with breast cancer". J. Clin. Oncol., 1999, 17, 1488.

[19] Ganz P.A., Coscarelli A., Fred C., Kahn B., Polinski M.L., Petersen L.: "Breast cancer survivors: Psychosocial concerns and quality of life". Breast Cancer Res. Treat., 1996, 38, 183.

[20] Mattson L.A., Cullberg G.: "Vaginal absorption of two estiol preparations. A comparative study in postmenopausal women". Acta Obstet. Gynecol. Scand.. 1983, 62, 393.

[21] Bygdeman M., Swahn M.L.: "Replens versus dienoestrol cream Ill the symptomatic treatment of vaginal atrophy in postmenopausal women". Maturitas, 1996, 23, 259.

[22] Gu M., Jacobsen J., Erroll M., Hoda S.A.: "Pap smears of patients on tamoxifen (Jett.)". Diag. Cytopathol., 1997, 16, 96.

[23] Abadi M.A., Barakat R.R.. Saigo P.E.: "Effects of tamoxifen on cervicovaginal smears from patients with breast cancer". Acta Cytol., 2000, 44. 141.

[24] Lahti E., Vuopala S., Kauppila A., Blanco G., Ruokonen A., Laatikainen T.:'"Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen". Gynecol. Oncol., 1994, 55, 410.

[25] Stern C.E., Tom P.M., Rios C.N.: "Cervicovaginal cytology 10 women treated with tamoxifen for breast carcinoma (abst.)". Arn. J . Clin. Pathol., 1998, 109, 485

[26] Coleman D.V ., Evans D.M.D.: "Biopsy Pathology and Cytology of the Cervix". London: Chapman and Hall, 1988.

[27] Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P.J., Laatiakainen T.: "Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen". Obstet. Gynecol., 1993, 81, 660.

[28] Corley D., Rowe J., Curtis M.T., Hogan W.M., Noumoff J.S., Livolsi V.A.: "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy". Obstet. Gynecol., 1992, 79, 111.

[29] Ascher S.M., Irnaoka I., Lage J.M.: "Tamoxifen-induced utenne abnormalities: the role of imaging". Radiolog)'， 2000, 214, 29.

[30] Buckley C.H., Fox H.: "Endometrial hyperplasia and inta-endometrial adenocarcinoma. In: Biopsy pathology of the endometrium". Buckley C.H., Fox H. (eds.). London: Chapman and Hall, 1989, 149.

[31] Kurrnan R.J., Norris H.J.: "Endometrial hyperplasia and related eellular changes". In: Kurman R.J., ed. Blaustein's pathology of the female genital tract. New York, Springer-Verlag, 1994, 411.

[32] Wilking N., lsaksson E., von Schoultz E.: "Tarnoxifen and secondary tumors. An update". Drug Safety, 1997, 16, 104

[33] Gal D., Kopel S., Bashevkin M., Lebowicz J., Lev R., Tancer L.: "Oncogenic potential on endornetria of postrnenopausal women with breast cancer: preliminary report". Gynecol. Oncol., 1991, 42, 120.

[34] Cheng W.F., Lin H.H., Torng P.L., Huang S.C.: "Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients". Gynecol. Oncol., 1997, 66, 233.

[35] Kedar R.P., Bourne T.H., Powles T.J., Collins WP., Ashley S.E., Cosgrove D.O. et al.: "Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial". Lancet, 1994, 343, 1318.

[36] Cohen I., Rosen D.J.D., Altaras M.M., Beyth Y., Shapira J., Yigael D.: "Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth". Br. J. Cancer, 1994, 63, 620.

[37] Barliere M., Carles A., Galant C., Donnez J.: "Uterine side effects of tamoxifen: a need for systematic pretreatment screening" Obstet. Gynecol., 1998, 91, 40.

[38] Karlsson B., Granberg S., Wikland M. et al.: "Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: a Nordic multicenter study". Am. J. Obstet. Gynecol., 1995, 172, 1488.

[39] Ismail S.M.: "Pathology of endometrium treated with tamoxifen" J. Clin. Pathol., 1994, 47, 827.

[40] Ismail S.M.: "Gynaecologic effects of tamoxifen". J. Clin. Pathol., 1999, 52, 83.

[41] Cohen I.. Rosen D.J.D., Shapira J. et al.: "Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer". Br. J. Obstet. Gynecol., 1993. 100, 567.

[42] De Muylder X., Neven P., De Somer M., Yan Bell Y., De Muylder V., De Muylder E.: "Endometrial lesions in patients undergoing tamoxifen therapy". Int. J. Gynecol. Ohstet., 1991, 36, 127.

[43] Malfetano J.H.:'Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients". Gynecol. Oncol., 1990, 39, 82.

[44] Schlesinger C., Seiryu K., Ascher S.M., Kendell M., Lage J.M., Silverberg S.G.: "Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups". Int. J. Gynecol. Pathol., 1998, 17, 302

[45] McGonigle K.F., Lantry S.A., Odommaryon T.L. et al.: "Histopathological effects of tamoxifen on the uterine epithelium of breast cancer patients-analysis by menopausal status". Cancer Lett., 1996, 101, 59.

[46] Nuovo M.A., Nuovo G.J., McCaffrey R.M. et al.: "Endometrial polyps in postmenopausal patients receiving tamoxifen". Int. J Gynecol. Pathol., 1989, 8, 125.

[47] Ramondetta L.M., Sherwood J.B., Dunton C.J., Palazzo J.P.: "Endometrial cancer in polyps associated with tamoxifen use". Am. J. Obstet. Gynecol., 1999, 180, 340.

[48] Neven P., Vergote I.: "Should tamoxifen users be screened for endometrial lesions?". Lancet, 1998, 351, 155.

[49] Bera! V.: "Prevention of cancers of the female genital tract". In: 'The Biology of Gynaecological Cancer". Leake R., Gore M., Ward R.H. (eds.). London: RCOG Press, 1995, 217.

[50] Adami H.-0., Krusemo U.B., Bergkvist L., Persson I., Pettersson B.: "On the age-dependent association between cancer of the breast and the endometrium. A nationwide cohort study". Br. J. Cancer, 1987, 55, 77.

[51] Stears V., Gelmann E.P.: "Does tamoxifen cause cancer in humans?". J. Clin. Oncol., 1998, 16, 779.

[52] Killackey M.A., Hakes T.B., Pierce V.K.: "Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens". Cancer Treat. Rep., 1985, 69, 237.

[53] Fornander T., Rutqvist LE., Wilking N.: "Effects of tamoxifen on the female genital tract". Ann. N. Y Acad. Sci., 1991, 622, 469.

[54] Rutqvist LE., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N.: "Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group". J. Natl. Cancer Inst., 1995, 87, 645.

[55] Sasco A.J., Chaplain G., Amoros E., Saez S.: "Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy". Epidemilogy, 1996, 7, 9.

[56] Van Leeuwen F.E., Benraadt J., Coebergh J.W.W. et al.: "Risk of endometrial career after tamoxifen treatment of breast cancer". Lancet, I 994, 343, 448.

[57] Early Breast Cancer Triallist's Collaborative Group: "Tamoxifen for early breast cancer: an overview of the randomized trials". Lancet, 1998, 351, 1451.

[58] Edwood J.M., Boyes D.A.: "Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens". Gynecol. Oneal., 1980, 10, 173.

[59] Magliples U., Naftolin F., Schartz P.E., Carcangiu M.L.: "Highgrade endometrial carcinoma in tamoxifen-treated breast cancer patients". J. Clin. Oneal., 1993, 11, 485.

[60] Silva E.G., Tornos C.S., Follen-Mitchell M.: "Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen". Int. J. Gynecol. Pathol., 1994, 13, 248.

[61] Timmerman D.. Deprest J., Vergote I.: "Tamoxifen-induced endometrial polyp". New Engl. J. Med., 1997, 336, 1389.

[62] American College of Obstetricians and Gynecologist. Committee on Gynecologic Practice: tamoxifen and endometrial cancer, no. 169. Washington, DC, American College of Obstetricians and Gynecologists. 1996, 1.

[63] Dilts P.V., Hopkins M.P., Chang A.E., Cody R.L.: "Rapid growth of leiomyoma in patient receiving tamoxifen". Am. J. Obstet. Gynecol., 1992, 166, 167.

[64] Ugwumadu A.H.N., Harding K.: "Uterine Ieiomyosarcoma and endometrial proliferation in postmenopausal women treated with the anti-oestrogen tamoxifen". Eur. J. Obstet. Gynecol., 1994, 54, 153.

[65] Kang J., Baxi L., Heller D.: "Tamoxifen induced growth of leiomyomas. A case report". J. Reprod. Med., 1996, 41, 119.

[66] Sabatini R., Fazio F.D.J., Loizzi P.: "Uterine leiomyosarcoma in a postmenopausal woman treated with tamoxifen: case report". Eur. J. Gynecol. Oncol., 1999, 20, 327.

[67] McCluggage W.G., McManus D.T., Lioe T.F.,Hill CM.: "Uterine carcinosarcoma in association with tamoxifen therapy". Br. J. Obstet. Gynecol., 1997, 104, 748.

[68] Cohen I.. Pere! E., Tepper R., Flex D., Figer A., Shapira J., Altaras M.M., Fishman Bernheim J., Cordoba M., Yigel D.. Beyth Y: "Dose-dependent effect of tamoxifen on endometrial pathologies in postmenopausal breast cancer patients". Breast Cancer Res Treat., 1998, I.

[69] Cohen I., Beth Y., Tepper R. et al.: "Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity?". Gynecol. Oncol., 1995, 58, 86.

[70] Clement P.B., Scully R.E.:'Tumors with mixed epithelial and mesenchymal elements. In: "Tumors and Tumor-Like Lesions of the Uterine Corpus and Cervix. Clement P.B., Young R.H. (eds.), New York: Churchill Livingstone, 1993, 329.

[71] Zaloudek C., Nourris H.J.: "Mesenchymal tumors of the uterus". In: Kurman R.J. (ed.) Blaustein's Pathology of the Female Genital Tract, Berlin, Heidelberg, New York: Springer, 1994, 487.

[72] Pautier P., Genestie C., Rey A., Morice Ph.. Roche B., Lhomme C., Haie-Meder Ch., Duvillard P.: "Analysis of clinicopathologic prognostic factor、for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma". Cancer, 2000, 88, 1425.

[73] Treilleux I., Mignotte H., Clement-Chassagne C., Guastalla P., Bailly C.: "Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium : report of six cases and review of the literature". Eur. J. Surg. Oneal., 1999, 25, 477.

[74] Barwick K.W., LiVolsi V.A.: "Heterologous mixed miillerian tumor confined to an endometrial polyp". Obstet. Gynecol., 1997, 53, 512.

[75] Clarke M.R.: "Uterine malignant mixed mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer" Gynecol. Oncol., 1993, 51, 411.

[76] Bocklage T., Lee K, Belinson J.L.: "Uterine Mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy" Gynecol. Oncol., 1992, 44, 104.

[77] Kerner H., Lichtig C.: "Miillerian adenocarcinoma presenting as cervical polyps: a report of a seven cases and review of the literature". Obstet. Gynecol., 1993, 81, 655.

[78] Zaloudek C.J., Norris H.J.: "Adenofibroma and adenosarcoma of the uterus". Cancer, 1981, 48, 354.

[79] Ungwumadu A.H.N., Harding K.: "Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the anti-estrogens tamoxifen". Eur. J. Obst. Gynecol. Reprod. Biol., 1994, 54, 153.

[80] Kimyay Y., Cengiz C., Tolunay S.: "Endometrial polyps, cystic glandular hyperplasia and atypical leiomyoma associated with tamoxifen therapy". Int. J. Gynecol. Obstet., 1994, 46, 69.

[81] Tosi P., Sforza V., Santopietro R.: "Estrogen receptor content, immunohistochemically determined by monoclonal antibodies in endometrial stromal sarcoma". Obstet. Gynecol., 1989, 73, 75.

[82] Chang K.L., Crabtree G.S., Lim-Tan S.K., Kempson R.L., Hendrickson M.R.: "Primary uterine endometrial sromal neoplasms. A clinicopathologic study of 117 cases". Am. J. Surg. Pathol., 1990, 14, 415.

[83] Klein W., Maier T., Geyer H., Pfleiderer A.: "Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance". Gynecol. Oncol., 1990, 38, 59.

[84] Sutton G.P., Stehman F.B., Michael H., Young P.C., Ehrlich C.E.: "Estrogen and progesterone receptors in uterine sarcomas" Obstet. Gynecol., 1986, 68, 709.

[85] Fotiou S., Hatjieleftheriou G., Kyrousis G., Kokka F., Apostolikas N.: "Long-term tamoxifen treatment: A possible aetiological factor in the development of uterine carcinosarcoma: Two case-reports and review of the literature". Anticancer Res., 2000, 20, 2015.

[86] Sreenan J.J., Hart W.R.: "Carcinosarcomas of the female genital tract". Am. J. Surg. Pathol., 1995, 19, 666.

[87] Chumas J.C., Mann W.J., Tseng L.: "Malignant mixed Mullenan tumor of the endometrium in a young woman with polycystic ovaries". Cancer, 1983, 52, 1478.

[881 Press M.F., Scully R.E.: "Endometrial'sarcomas'complicating ovarian thecoma polycystic ovarian disease and estrogen therapy" Gynecol. Oncol., 1985, 21, 135.

[89] Evans M.J., Langlois N.E.I., Kitchener H.C., Miller I.D.: "Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Mullerian tumor) of the uterus?". Int. J. Gynecol. Cancer, 1995, 5, 310.

[90] Altaras M.M., Aviram R., Cohen I. et al.: "Case report. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas". Gynecol. Oncol., 1993, 49, 255.

[91] McCluggage W.G., Abdulkader M., Price J.H., Kelehan P., Hamilton S., Beattie J., Al-Nafussi A.: "Uterine carcinosarcoma in patients receiving tamoxifen. A report of 19 cases". Int. J. Gynecol. Cancer, 2000, 10, 280.

[92] Arici D.S., Aker H., Yildiz E., Tasyurt A.: "Mullerian adenosarcoma of the uterus associated with tamoxifen therapy". Arch Gynecol. Obstet., 2000, 264, 105.

[93] Clement P.B.,O liva E.,Y oung R.H.: "Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions". Int. J. Gynecol. Pathol., 1996, 15, 222.

[94] Czernobilsky B., Mercer B.L.: "Endometrial pathology". Curr. Opin. Obstet. Gynecol., 1997, 9, 52.

[95] Jagavkar R.S.,S hakespeare T.P.,S tevevs M.J.: "Endometrial adenosarcoma with adjuvant therapy for breast carcinoma". Aust. Radiol., 1998, 42, 157.

[96] Kennedy M.M., Baigre C.F., Manek S.: "Tamoxifen and the endometrium: review of 102 cases and comparison with HRTrelated and non HRT related endometrial pathology". Int. J. Gynecol. Pathol., 1999, 18, 130.

[97] Ostor A.G., Rollason T.P.: "Mixed tumors of the uterus". In: Fox H. (ed.). Obstetrical and Gynaecological Pathology, New York Churchill Livingstone, 1995, 587.

[98] Klopper A., Hall M.: "New synthetic agent for the induction of ovulation. Preliminary trial in women". Br. J. Med., 1971, 2, 152.

[99] Barbieri R.L., Ferracci A.L., Droesch J.N., Rochelson B.L.: "Ovarian torsion in a premenopausal woman treated for breast cancer". Fertil. Steril., 1993, 59, 459.

[100] Varras M., Stylianidou A., Akrivis Ch., Galanis P., Stefanaki S., Antoniou N.: "Extamedullary hematopoiesis in the uterine isthmus: A case report and review of the literature". Eur. J. Gynecol. Oncol., 2002, 22, 227.

[101] Bryant A.J.S., Weir J.A.: "Prophylactic oophorectomy m operable instances of carcinoma of the breast". Surg. Gynecol. Obstet., 1981, 153, 660.

[102] Nomura Y., Shirouzu M., Takayama T.: "Direct comparison of adjuvant endocrine therapy, chemotherapy and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptors and menopausal status". Breast Cancer Res. Treat., 1998, 49, 51.

[103] Hajjar L.R., Kim W., Nolan G.H., Turner S., Raju U.R.: "Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: Report of a case". Obstet. Gynecol., 1993, 82 (suppl.), 642